Eukaryotic layered vector initiation systems
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsThomas W. Dubensky, Jr., John M Polo, Carlos E Ibanez, Stephen M. W. Chang, Douglas J Jolly, David A Driver, Barbara A Belli
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
Claims4
A method of inhibiting binding of a first ligand to a receptor, comprising introducing into a eukaryotic cell a eukaryotic layered vector initiation system which comprises a eukaryotic promoter 5′ of alphaviral cDNA, wherein the eukaryotic promoter initiates within the eukaryotic cell 5′ to 3′ synthesis of alphaviral RNA from the alphaviral cDNA;
- wherein the alphaviral RNA comprises a vector that autonomously amplifies in the eukaryotic cell;
- wherein the vector comprises:
- (1) a 5′ sequence capable of initiating transcription of alphaviral RNA,
- (2) an RNA that encodes alphaviral nonstructural proteins,
- (3) an alphaviral RNA polymerase recognition sequence, and
- (4) a heterologous RNA which encodes a second ligand,
- whereby the second ligand binds to the receptor, thereby blocking binding of the first ligand.
Dependencies are inferred from the claim text.